On Oct 28, 2019, Ascentage Pharma Group International (6855.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
Huatai Financial was the Joint Global Coordinator for the deal.
Ascentage issued 12.18 million shares worldwide at an issue price of HK$34.20 per share, raising a total amount of HK$417 million (before the exercise of the over-allotment option).
Ascentage is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. Leveraging the technical expertise in structure-based drug design and innovative drug discovery engine, the Company has developed a robust pipeline of eight clinical stage small molecule drug candidates.